Concepedia

David Muccino

DM

Statistics

Publications

15

Citations

2.3K

H-Index

12

Active since

1998

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

King's College London

Hull York Medical School

Queen's University Belfast

Manchester University NHS Foundation Trust

David Muccino is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, cough management, and cough severity assessment.

Publications per year

1998–2022

15

Publications

15

Modification of gene activity in mouse embryos in utero by a tamoxifen-inducible form of Cre recombinase

Paul S. Danielian, David Muccino, David H. Rowitch et al. · Current Biology · 1998 · 1.3K citations · Full text

, , +17

Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials

Lorcan McGarvey, Surinder S. Birring, Alyn H. Morice et al. · The Lancet · 2022 · 312 citations · Full text

, , +11

Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial

John A. Smith, Michael M. Kitt, Alyn H. Morice et al. · The Lancet Respiratory Medicine · 2020 · 224 citations · Full text

, , +8

Validation of a visual analog scale for assessing cough severity in patients with chronic cough

Allison Martin Nguyen, Elizabeth D. Bacci, Margaret Vernon et al. · Therapeutic Advances in Respiratory Disease · 2021 · 115 citations · Full text

, , +15

Leicester Cough Questionnaire validation and clinically important thresholds for change in refractory or unexplained chronic cough

Allison Martin Nguyen, Jonathan Schelfhout, David Muccino et al. · Therapeutic Advances in Respiratory Disease · 2022 · 76 citations · Full text

, , +15

1–5 of 15